Cargando…
181. Impact of Rapid Diagnostic Technology on Patients with Candidemia
BACKGROUND: Candida spp. are the fourth most common cause of bloodstream infections (BSI) in the United States and have an associated mortality rate of 19-40.5%. Mortality rates are further impacted by delay in time to adequate antifungal therapy, historically due to delayed time to identification o...
Autores principales: | Funderburk, Patrick, Carr, Amy L, Hayes, Jillian E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752172/ http://dx.doi.org/10.1093/ofid/ofac492.259 |
Ejemplares similares
-
Risk Factors for Candidemia as Compared with Patients with Negative Blood Cultures Placed on Empiric Micafungin
por: Carr, Amy, et al.
Publicado: (2017) -
919. Let’s GO PO: Impact of Monthly Feedback on a Longitudinal Intravenous to Oral Antimicrobial Conversion Initiative
por: Hayes, Jillian E, et al.
Publicado: (2022) -
Impact of Infectious Diseases Consultation on Mortality in Patients with Candidemia
por: Mejia, Carlos, et al.
Publicado: (2017) -
1166. Evaluating the Impact of the 2016 Candidemia Guidelines on the Incidence of Ocular Complications of Candidemia
por: Hillenbrand, Molly, et al.
Publicado: (2020) -
2117. Fluconazole vs. Echinocandins as Initial Therapy for Candidemia Caused by Fluconazole-Susceptible Species in the Era of Rapid Diagnostic Testing
por: Roshdy, Danya, et al.
Publicado: (2019)